• Mutation; HGNC; HGNC:3691; FGFR4; Simple; p.Val550Leu (c.1648G>C); Zygosity=Unspecified (PubMed=22142829).
  

PubMed=12370270; DOI=10.1172/JCI15634; PMCID=PMC151148
Panigrahy D., Singer S., Shen L.Q., Butterfield C.E., Freedman D.A., Chen E.J., Moses M.A., Kilroy S., Duensing S., Fletcher C.D.M., Fletcher J.A., Hlatky L., Hahnfeldt P., Folkman J., Kaipainen A.
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis.
J. Clin. Invest. 110:923-932(2002)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056; PMCID=PMC3271129
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=23882450; DOI=10.3389/fonc.2013.00183; PMCID=PMC3713458
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183.1-183.12(2013)

PubMed=23665679; DOI=10.1038/onc.2013.129
Sokolowski E., Turina C.B., Kikuchi K., Langenau D.M., Keller C.
Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.
Oncogene 33:1877-1889(2014)